Literature DB >> 27528813

Evolution of management in peritoneal surface malignancies.

Emel Canbay1, Bahar Canbay Torun2, Ege Sinan Torun3, Yutaka Yonemura1.   

Abstract

Management of peritoneal surface malignancies has gradually evolved by the introduction of cytoreductive surgery in combination with intraperitoneal chemotherapy applications. Recently, peritoneal metastases of intraabdominal solid organ tumors and primary peritoneal malignancies such as peritoneal mesothelioma are being treated with this new approach. Selection criteria are important to reduce morbidity and mortality rates of patients who will experience minimal or no benefit from these combined treatment modalities. Management of peritoneal surface malignancies with this current trend is presented in this review.

Entities:  

Keywords:  Heated chemotherapy; colorectal cancer; gastric cancer; mesothelioma; ovarian cancer; peritoneal metastases

Year:  2015        PMID: 27528813      PMCID: PMC4970780          DOI: 10.5152/UCD.2016.3375

Source DB:  PubMed          Journal:  Ulus Cerrahi Derg        ISSN: 1300-0705


  63 in total

1.  Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.

Authors:  J Spiliotis; E Halkia; E Lianos; N Kalantzi; A Grivas; E Efstathiou; S Giassas
Journal:  Ann Surg Oncol       Date:  2014-11-13       Impact factor: 5.344

Review 2.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

3.  Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.

Authors:  Emel Canbay; Akiyoshi Mizumoto; Masumi Ichinose; Haruaki Ishibashi; Shouzou Sako; Masamitsu Hirano; Nobuyuki Takao; Yutaka Yonemura
Journal:  Ann Surg Oncol       Date:  2013-12-20       Impact factor: 5.344

4.  Long-term survival of peritoneal carcinomatosis of colorectal origin.

Authors:  Vic J Verwaal; Serge van Ruth; Arjen Witkamp; Henk Boot; Gooike van Slooten; Frans A N Zoetmulder
Journal:  Ann Surg Oncol       Date:  2004-12-27       Impact factor: 5.344

Review 5.  A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy.

Authors:  W Yu
Journal:  Eur J Surg Oncol       Date:  2006-04-18       Impact factor: 4.424

6.  Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.

Authors:  Dario Baratti; Shigeki Kusamura; Daisuke Nonaka; Antonello Domenico Cabras; Barbara Laterza; Marcello Deraco
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

Authors:  Dominique Elias; Jérémie H Lefevre; Julie Chevalier; Antoine Brouquet; Frédéric Marchal; Jean-Marc Classe; Gwenaël Ferron; Jean-Marc Guilloit; Pierre Meeus; Diane Goéré; Julia Bonastre
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544

9.  Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer.

Authors:  M Ikeguchi; A Oka; S Tsujitani; M Maeta; N Kaibara
Journal:  Anticancer Res       Date:  1994 Sep-Oct       Impact factor: 2.480

10.  The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer.

Authors:  Francisco C Muñoz-Casares; Sebastián Rufián; María J Rubio; Carlos J Díaz; Rafael Díaz; Angela Casado; Alvaro Arjona; María C Muñoz-Villanueva; Jordi Muntané
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.